GSK presented at the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices meeting that FLUARIX® QUADRIVALENT demonstrated 63.2% efficacy against moderate to severe influenza and 49.8% efficacy against influenza of any severity in children 6 months through 35 months of age.

These results are based on a randomized, observer-blind, non-influenza vaccine-controlled trial that enrolled 12,018 children in five independent cohorts in 13 countries in Asia, Europe, and Central America from 2011 through the end of 2014.

FLUARIX® QUADRIVALENT was immunogenic against all four vaccine strains (i.e., A/H1N1, A/H3N2, B/Victoria and B/Yamagata).

The safety and reactogenicity profile was similar to vaccines used in the same age group. No safety signal was observed.

Additionally, the study found that FLUARIX® QUADRIVALENT reduced healthcare utilization (i.e., antibiotic use, general practitioner visits and emergency department visits) related to confirmed influenza illness.